Attana´s customer InDex Pharmaceuticals publishes mechanism of action data for their drug candidate cobitolimod

Attana´s customer InDex Pharmaceuticals publishes mechanism of action data for their drug candidate cobitolimod

InDex Pharmaceuticals Holding AB (publ) announced on February 25th the publication of scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate in development for the treatment of moderate to severe ulcerative colitis. The paper, published in the peer-reviewed Journal of Crohns and Colitis (JCC), shows that the Toll-like receptor 9 (TLR9) agonist cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response. The publication has also been highlighted in the journal podcast. Attana´s QCM technology was applied to understand and verify the target specificity of the cobitolimod prior to in vivo tests in mice.

Cobitolimod recently met the primary endpoint in the phase IIb dose optimisation study CONDUCT as a novel therapy for moderate to severe ulcerative colitis with an outstanding combination of efficacy and safety. Ulcerative colitis is a debilitating chronic disease caused by inflammation of the large intestine. Accumulating evidence indicates that an imbalance between T helper 17 (Th17) and T regulatory (Treg) cells and their associated cytokines creates a pro-inflammatory state in ulcerative colitis. The scientific data now published in JCC demonstrate that cobitolimod mediates immunomodulatory effects both in an experimental colitis model as well as in blood and tissue samples of ulcerative colitis patients leading to a rebalanced Th17/Treg cell immune response.

We are very pleased with the publication of these results, which provide a deeper understanding of how cobitolimod mediates its anti-inflammatory effects. That JCC also chooses to highlight the data in their podcast, shows that there is a great interest from the scientific community,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. “This supporting mechanistic data fits very nicely with the successful clinical results obtained with cobitolimod in our phase IIb study CONDUCT.”

Read the full press release from InDex Pharmaceuticals Holding AB (publ) here:

Attana AB has no financial interest in this project. The Attana related work has been performed as contract research work where Attana since previously has received full payment.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact  sales@attana.com

Tags:

About Us

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.

Subscribe

Media

Media

Documents & Links